Azacitidine, Venetoclax, and Gilteritinib

A Phase I/II Study of Azacitidine, Venetoclax, and Gilteritinib for Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome With an Activating FLT3 Mutation

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1/2
Enrollment
97 patients (estimated)
Sponsors
MD Anderson Cancer Center
Tags
Antimetabolites, BCL-2 Inhibitor, Hypomethylating Agents (HMA), Tyrosine Kinase (TK) Inhibitor
Trial Type
Treatment
Last Update
10 months ago
SparkCures ID
1550
NCT Identifier
NCT04140487

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.